For women not responding well to denosumab, adding a second drug boosted spine density, proof that bone care is personal.
Not every patient responds to treatment the same way, and one of the most frustrating moments in osteoporosis care is when someone is doing everything right and their numbers still aren't where we'd like. A December 2025 study offers a genuinely encouraging answer.
In postmenopausal women with severe osteoporosis already taking denosumab, researchers added a second medication, romosozumab. The combination increased bone density in the spine and sustained bone formation, supporting the use of combination therapy specifically when the response to denosumab alone hasn't been enough.
What I take from this isn't “everyone needs two drugs.” It's that we have more tools than ever, and we're learning how to sequence and combine them thoughtfully for people who need more.
The art of this field has always been matching the right therapy to the right person, and adjusting when the body tells us the current plan isn't doing the job.
If you're on treatment for osteoporosis and your bone density isn't improving the way you hoped, that's not a dead end. It's a signal to revisit the plan with a specialist who knows the full menu of options.
Wondering about your own bone health?
Book a ConsultationIn postmenopausal women with severe osteoporosis already on denosumab, adding romosozumab increased lumbar-spine bone density and sustained bone formation, supporting combination therapy when the denosumab response is inadequate.
